EDAP vs. ATAI, KOD, PSTX, OCGN, SERA, CHRS, CMPX, VSTM, AURA, and PRLD
Should you be buying Edap Tms stock or one of its competitors? The main competitors of Edap Tms include Atai Life Sciences (ATAI), Kodiak Sciences (KOD), Poseida Therapeutics (PSTX), Ocugen (OCGN), Sera Prognostics (SERA), Coherus BioSciences (CHRS), Compass Therapeutics (CMPX), Verastem (VSTM), Aura Biosciences (AURA), and Prelude Therapeutics (PRLD). These companies are all part of the "medical" sector.
Edap Tms (NASDAQ:EDAP) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.
Edap Tms received 21 more outperform votes than Atai Life Sciences when rated by MarketBeat users. However, 65.71% of users gave Atai Life Sciences an outperform vote while only 63.05% of users gave Edap Tms an outperform vote.
Edap Tms has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.
Edap Tms has higher revenue and earnings than Atai Life Sciences. Edap Tms is trading at a lower price-to-earnings ratio than Atai Life Sciences, indicating that it is currently the more affordable of the two stocks.
Edap Tms has a net margin of -37.67% compared to Atai Life Sciences' net margin of -20,043.11%. Edap Tms' return on equity of -32.37% beat Atai Life Sciences' return on equity.
Edap Tms currently has a consensus price target of $13.67, indicating a potential upside of 92.49%. Atai Life Sciences has a consensus price target of $17.50, indicating a potential upside of 877.65%. Given Atai Life Sciences' higher possible upside, analysts clearly believe Atai Life Sciences is more favorable than Edap Tms.
In the previous week, Atai Life Sciences had 1 more articles in the media than Edap Tms. MarketBeat recorded 10 mentions for Atai Life Sciences and 9 mentions for Edap Tms. Atai Life Sciences' average media sentiment score of 0.46 beat Edap Tms' score of 0.09 indicating that Atai Life Sciences is being referred to more favorably in the news media.
62.7% of Edap Tms shares are owned by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are owned by institutional investors. 0.2% of Edap Tms shares are owned by insiders. Comparatively, 30.0% of Atai Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Atai Life Sciences beats Edap Tms on 9 of the 16 factors compared between the two stocks.
Get Edap Tms News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDAP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Edap Tms Competitors List
Related Companies and Tools